CVC Capital Partners Is Said to Near $2.6 Billion Deal for Pharma Firm Cooper
- Buyout firm negotiating terms with Cooper’s owner Charterhouse
- CVC beats out rivals including consortium led by PAI Partners
This article is for subscribers only.
CVC Capital Partners is nearing a deal to acquire European over-the-counter drugmaker Cooper for about 2.2 billion euros ($2.6 billion), people familiar with the matter said.
The private equity firm is negotiating detailed terms of an agreement with Cooper’s owner, Charterhouse Capital Partners, according to the people. CVC beat out rival suitors including a consortium backed by PAI Partners and Ontario Teachers’ Pension Plan, the people said, asking not to be identified because the information is private.